CC
PCRX icon

Clearline Capital’s Pacira BioSciences PCRX Stock Holding History

Clearline Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-136,658
Closed -$3.99M – 156
2024
Q1 		$3.99M Sell
136,658
-194,119
-59% -$5.96M 0.19% 61
2023
Q4 		$11.2M Buy
330,777
+31,485
+11% +$921K 0.68% 26
2023
Q3 		$9.18M Buy
+299,292
New +$10.8M 0.79% 36

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearline Capital's PCRX Position: Q2 2024 in Review

Clearline Capital sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 136,658 shares — an estimated $3.99M sold.

Clearline Capital first reported a position in PCRX in Q3 2023 and held it in 3 quarters. The position peaked at $11.2M in Q4 2023. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Clearline Capital reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Clearline Capital sold 136,658 Pacira BioSciences shares in Q2 2024, an estimated $3.99M.
  • Clearline Capital first reported a position in Pacira BioSciences in Q3 2023 and held it in 3 quarters.
  • Clearline Capital's Pacira BioSciences position peaked at $11.2M in Q4 2023.
  • 280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Clearline Capital's 13F filing for Q2 2024, filed 15 Aug 2024.